-
International Journal of Nephrology and Renovascular Disease
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Level of 8-OHdG in drained dialysate appears to be a marker of peritoneal damage in peritoneal dialysis
Original Research
(668) Views (148) Full article downloads
Authors: Morishita Y, Watanabe M, Hirahara I, Akimoto T, Muto S, Kusano E
Published Date December 2011
Volume 2012:5 Pages 9 - 14
DOI: http://dx.doi.org/10.2147/IJNRD.S27553
Yoshiyuki Morishita, Minami Watanabe, Ichiro Hirahara, Tetsu Akimoto, Shigeaki Muto, Eiji KusanoDivision of Nephrology, Department of Medicine, Jichi Medical University, Tochigi, Japan
Purpose: Peritoneal dialysis (PD) is a successful renal replacement therapy; however, long-term PD leads to structural and functional peritoneal damage. Therefore, the monitoring and estimation of peritoneal function are important in PD patients. Oxidative stress has been implicated as one possible mechanism of peritoneal membrane damage. The aim of this study was to evaluate the association between an oxidative stress marker, 8-hydroxydeoxyguanosine (8-OHdG), and peritoneal damage in PD patients.
Methods: The authors evaluated 8-OHdG in drained dialysate by enzyme immunoassay to investigate the association between 8-OHdG and solute transport rate estimated by peritoneal equilibration test and matrix metalloproteinase-2 (MMP-2) level in 45 samples from 28 PD patients.
Results: The 8-OHdG level was significantly correlated with dialysate:plasma creatine ratio (r = 0.463, P < 0.05) and significantly inversely correlated with D/D0 glucose (where D is the glucose level of peritoneal effluents obtained 4 hours after the injection and D0 is the glucose level obtained immediately after the injection) (r = -0.474, P < 0.05). The 8-OHdG level was also significantly correlated with MMP-2 level (r = 0.551, P < 0.05), but it was not correlated with the age of subjects, the duration of PD, or blood pressure.
Conclusion: The level of 8-OHdG in drained dialysate may be a useful novel marker of peritoneal damage in PD.
Keywords: oxidative stress, solute transport rate, MMP-2, peritoneal equilibration test
Other articles by Dr Yoshiyuki Morishita
Readers of this article also read:
A pilot study of the impact of high-frequency chest wall oscillation in chronic obstructive pulmonary disease patients with mucus hypersecretion
Efficacy and safety of prolonged-release melatonin for insomnia in middle-aged and elderly patients with hypertension: a combined analysis of controlled clinical trials
Correlation between radioactivity and chemotherapeutics of the 111In-VNB-liposome in pharmacokinetics and biodistribution in rats
Challenges for heart disease stem cell therapy
Intraocular pressure reduction of fixed combination timolol maleate 0.5% and dorzolamide 2% (Cosopt) administered three times a day
Outcome of the HORIZONS-AMI trial: bivalirudin enhances long-term survival in patients with ST-elevation myocardial infarction undergoing angioplasty
Local pulmonary administration of factor VIIa (rFVIIa) in diffuse alveolar hemorrhage (DAH) – a review of a new treatment paradigm
Nebivolol: impact on cardiac and endothelial function and clinical utility
Emerging drug combinations to optimize renovascular protection and blood pressure goals
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio
- Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs
- Potential renovascular hypertension, space missions, and the role of magnesium
- The use of everolimus in renal-transplant patients
- Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate




